GSK trades 42% below pharma peers as HIV injectables grow, Nuvalent adds oncology launches, and hep B catalyst nears.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results